Elizabeth H Bruenderman1, Robert C G Martin2. 1. Department of Surgery, University of Louisville, Louisville, Kentucky. 2. Department of Surgery, University of Louisville, Louisville, Kentucky. Electronic address: Robert.Martin@louisville.edu.
Abstract
BACKGROUND: Pancreatic cancer (PC) is one of the most deadly forms of cancer in the United States, with an annual incidence to death ratio of 0.92 because of the late stage at diagnosis. Identification of high-risk individuals (HRIs) that would be ideal for screening is needed to identify precursor lesions and small early stage disease. Those with a genetic predisposition have largely been identified, but little is known about those at high-risk for sporadic PC. This study asserts that a high-risk population does exist in sporadic pancreatic adenocarcinoma and proposes simple guidelines for screening. METHODS: A systematic review was conducted of the literature regarding identification of and screening in high-risk groups. RESULTS: Those with the highest genetic risk of developing PC include those with hereditary pancreatitis (87 times more likely at age 55), Peutz-Jehgers syndrome (132 times more likely at age 50), p16-Leiden mutations (48 times more likely), and familial pancreatic cancer (FPC) kindreds (32 times more likely). Those with the highest risk of developing sporadic PC include those with new-onset diabetes older than 50 y and smoking history. CONCLUSIONS: Given that sporadic PC is the single largest patient population effected with this devastating disease, some form of screening should be initiated. Currently, the medical community does nothing to attempt early detection of PC. However, sufficient evidence now exists to begin a screening protocol in a high-risk cohort, which would be patients with new-onset diabetes older than 50 y and a smoking history.
BACKGROUND:Pancreatic cancer (PC) is one of the most deadly forms of cancer in the United States, with an annual incidence to death ratio of 0.92 because of the late stage at diagnosis. Identification of high-risk individuals (HRIs) that would be ideal for screening is needed to identify precursor lesions and small early stage disease. Those with a genetic predisposition have largely been identified, but little is known about those at high-risk for sporadic PC. This study asserts that a high-risk population does exist in sporadic pancreatic adenocarcinoma and proposes simple guidelines for screening. METHODS: A systematic review was conducted of the literature regarding identification of and screening in high-risk groups. RESULTS: Those with the highest genetic risk of developing PC include those with hereditary pancreatitis (87 times more likely at age 55), Peutz-Jehgers syndrome (132 times more likely at age 50), p16-Leiden mutations (48 times more likely), and familial pancreatic cancer (FPC) kindreds (32 times more likely). Those with the highest risk of developing sporadic PC include those with new-onset diabetes older than 50 y and smoking history. CONCLUSIONS: Given that sporadic PC is the single largest patient population effected with this devastating disease, some form of screening should be initiated. Currently, the medical community does nothing to attempt early detection of PC. However, sufficient evidence now exists to begin a screening protocol in a high-risk cohort, which would be patients with new-onset diabetes older than 50 y and a smoking history.
Authors: Robert R McWilliams; Eric D Wieben; Kari G Rabe; Katrina S Pedersen; Yanhong Wu; Hugues Sicotte; Gloria M Petersen Journal: Eur J Hum Genet Date: 2010-12-08 Impact factor: 4.246
Authors: Rahul Pannala; Cynthia L Leibson; Kari G Rabe; Lawrence J Timmons; Jeanine Ransom; Mariza de Andrade; Gloria M Petersen; Suresh T Chari Journal: Am J Gastroenterol Date: 2009-06-09 Impact factor: 10.864
Authors: Alison P Klein; Kieran A Brune; Gloria M Petersen; Michael Goggins; Anne C Tersmette; G Johan A Offerhaus; Constance Griffin; John L Cameron; Charles J Yeo; Scott Kern; Ralph H Hruban Journal: Cancer Res Date: 2004-04-01 Impact factor: 12.701
Authors: Rahul Pannala; Jeffery B Leirness; William R Bamlet; Ananda Basu; Gloria M Petersen; Suresh T Chari Journal: Gastroenterology Date: 2008-01-18 Impact factor: 22.682
Authors: Femke A de Snoo; D Timothy Bishop; Wilma Bergman; Inge van Leeuwen; Clasine van der Drift; Frans A van Nieuwpoort; Coby J Out-Luiting; Hans F Vasen; Jeanet A C ter Huurne; Rune R Frants; Rein Willemze; Martijn H Breuning; Nelleke A Gruis Journal: Clin Cancer Res Date: 2008-11-01 Impact factor: 12.531
Authors: Barbara A Hocevar; Lisa M Kamendulis; Xinzhu Pu; Susan M Perkins; Zheng-Yu Wang; Erica L Johnston; John M DeWitt; Lang Li; Patrick J Loehrer; James E Klaunig; E Gabriela Chiorean Journal: PLoS One Date: 2014-03-20 Impact factor: 3.240
Authors: Lianne Scholten; Anouk Ej Latenstein; Cora M Aalfs; Marco J Bruno; Olivier R Busch; Bert A Bonsing; Bas Groot Koerkamp; I Quintus Molenaar; Dirk T Ubbink; Jeanin E van Hooft; Paul Fockens; Jolanda Glas; J Hans DeVries; Marc G Besselink Journal: United European Gastroenterol J Date: 2020-07-23 Impact factor: 4.623